Hangzhou Tigermed Consulting Co Ltd 2018 SR
The report summarizes Tigermed's corporate social responsibility activities from 2012 to 2018, highlighting its role as a leading clinical CRO. Key achievements include participating in 166 domestic innovative drug trials and investing RMB 88.03 million in R&D in 2018. The company emphasizes quality management, employee development with 80% female staff, and social initiatives like the Project of Zero HBV Transmission from Mother to Child. It also aligns its future strategy with four UN Sustainable Development Goals to promote health and industry innovation.
Company: Hangzhou Tigermed Consulting Co Ltd
Sector: Professional & technical services
Country: China
Year: 2018
Type: SR
Pages: 12
Back to company
Hangzhou Tigermed Consulting Co Ltd
Corporate Social Responsibility Summary Report
The report summarizes Tigermed's corporate social responsibility activities from 2012 to 2018, highlighting its role as a leading clinical CRO. Key achievements include participating in 166 domestic innovative drug trials and investing RMB 88.03 million in R&D in 2018. The company emphasizes quality management, employee development with 80% female staff, and social initiatives like the Project of Zero HBV Transmission from Mother to Child. It also aligns its future strategy with four UN Sustainable Development Goals to promote health and industry innovation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
2012 - 2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Sustainable Development Goals
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees